| Unique ID issued by UMIN | UMIN000063671 |
|---|---|
| Receipt number | R000072817 |
| Scientific Title | Changes in Vascular Endothelial-Related Biomarkers Before and After Nerandomilast Initiation and Their Association with Pulmonary Function |
| Date of disclosure of the study information | 2026/11/18 |
| Last modified on | 2026/11/18 00:21:44 |
Changes in Vascular Endothelial-Related Biomarkers Before and After Nerandomilast Initiation and Their Association with Pulmonary Function
NERA-ENDO Study
Changes in Vascular Endothelial-Related Biomarkers Before and After Nerandomilast Initiation and Their Association with Pulmonary Function
NERA-ENDO Study
| Japan |
Fibrotic interstitial lung disease
| Pneumology |
Others
NO
This study aims to evaluate changes in serum levels of syndecan-1 (SDC-1), soluble E-selectin (sE-selectin), and soluble vascular cell adhesion molecule-1 (sVCAM-1) in patients with interstitial lung disease starting nerandomilast treatment and to examine their association with changes in forced vital capacity (FVC) over 6 months. Serum biomarker levels will be measured at baseline and at 3 and 6 months after treatment initiation. As a secondary objective, we will examine whether changes in these biomarkers during the first 3 months are associated with changes in FVC from baseline to 6 months.
Efficacy
The association between the absolute change in forced vital capacity (FVC, mL) from baseline to 6 months after nerandomilast initiation and changes in serum SDC-1, sE-selectin, and sVCAM-1 over the same period. This association will be assessed using the overall F-test in a multiple linear regression model including changes in all three biomarkers as independent variables.
Observational
| 18 | years-old | <= |
| 999 | years-old | > |
Male and Female
1. Patients aged 18 years or older with fibrotic interstitial lung disease.
2. Patients who are considered eligible for nerandomilast treatment by their treating physician in routine clinical practice and are scheduled to initiate nerandomilast. Prior or concomitant treatment with nintedanib, pirfenidone, corticosteroids, or immunosuppressants is permitted.
3. Patients who have received sufficient information about the study and provided written informed consent.
1. Patients without an available serum sample obtained before nerandomilast initiation. Missing serum samples at 3 or 6 months after enrollment will be treated as missing data and will not result in exclusion from the study.
2. Patients unable to undergo pulmonary function testing. Missing pulmonary function test data at 3 or 6 months after enrollment will not result in exclusion from the study and will be treated as missing data.
3. Patients deemed unsuitable for study participation by the principal investigator or treating physician.
60
| 1st name | Yusuke |
| Middle name | |
| Last name | Nakamura |
Dokkyo Medical University Hospital
Department of Pulmonary Medicine and Clinical Immunology
321-0207
880 Kitakobayashi, Mibu, Tochigi, JAPAN
0282872151
nakamuyu@dokkyomed.ac.jp
| 1st name | Yusuke |
| Middle name | |
| Last name | Nakamura |
Dokkyo Medical University Hospital
Department of Pulmonary Medicine and Clinical Immunology
321-0207
880 Kitakobayashi, Mibu, Tochigi, JAPAN
0282-87-2151
nakamuyu@dokkyomed.ac.jp
Dokkyo Medical University Hospital, Department of Pulmonary Medicine and Clinical Immunology
none
Other
Dokkyo Medical University Hospital Clinical Research Review Committee
880 Kitakobayashi, Mibu, Tochigi, JAPAN
0282-86-1111
none
NO
獨協医科大学病院(栃木県)
| 2026 | Year | 11 | Month | 18 | Day |
Unpublished
Enrolling by invitation
| 2026 | Year | 09 | Month | 06 | Day |
| 2026 | Year | 10 | Month | 23 | Day |
| 2026 | Year | 10 | Month | 23 | Day |
| 2031 | Year | 09 | Month | 30 | Day |
none
| 2026 | Year | 11 | Month | 18 | Day |
| 2026 | Year | 11 | Month | 18 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000072817